Instituto de Química Médica (CSIC), Juan de Cierva 3, 28006 Madrid, Spain.
Eur J Med Chem. 2012 Dec;58:98-111. doi: 10.1016/j.ejmech.2012.10.015. Epub 2012 Oct 17.
By applying a diversity oriented synthesis strategy for the search of new antagonists of the thrombin receptor PAR1, a series of peptide-based ureas and thioureas, including analogues of the PAR1 reference antagonist RWJ-58259, has been designed and synthesized. The general synthetic scheme involves reduction of basic amino acid-derived amino nitriles by hydrogen transfer from hydrazine monohydrate in the presence of Raney Ni, followed by reaction with diverse isocyanates and isothiocyanates, and protecting group removal. All new compounds have been evaluated as inhibitors of human platelet aggregation induced by the PAR1 agonist SFLLRN. Some protected peptide-based ureas displayed significant antagonist activity.
通过应用多样性导向合成策略来寻找新的血栓酶受体 PAR1 拮抗剂,设计并合成了一系列基于肽的脲和硫脲,包括 PAR1 参考拮抗剂 RWJ-58259 的类似物。一般的合成方案包括在雷尼镍存在下,通过水合肼的氢转移还原碱性氨基酸衍生的氨基腈,然后与各种异氰酸酯和异硫氰酸酯反应,并去除保护基。所有新化合物均被评估为 PAR1 激动剂 SFLLRN 诱导的人血小板聚集的抑制剂。一些保护的基于肽的脲表现出显著的拮抗活性。